Low-Dose Initiation of Buprenorphine : A Narrative Review
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE OF REVIEW: Opioid use disorder (OUD) is a chronic disorder in which a person loses control over the use of opioids, develops a compulsive behavior, and defends the use despite knowing the negative consequences. There are numerous treatments for OUD, including buprenorphine. Since it is displacing a full agonist opioid, precipitated withdrawal can occur with standard inductions involving buprenorphine.
RECENT FINDINGS: Case reports have noted success with a low-dose initiation of buprenorphine, which is different from typical protocols, relatively limited by adverse effects when patients were recently administered full agonists. A cohort investigation studied the use of a transdermal patch as part of the protocol, which was fairly well tolerated. While ongoing research is being conducted on this topic, recent case studies and smaller cohort studies have demonstrated the feasibility of a trial to treat OUD with low-dose initiation of buprenorphine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Current pain and headache reports - 27(2023), 7 vom: 21. Juli, Seite 175-181 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Edinoff, Amber N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
40D3SCR4GZ |
|---|
| Anmerkungen: |
Date Completed 02.06.2023 Date Revised 02.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11916-023-01116-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355876620 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355876620 | ||
| 003 | DE-627 | ||
| 005 | 20231226065256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11916-023-01116-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355876620 | ||
| 035 | |a (NLM)37083890 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Edinoff, Amber N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low-Dose Initiation of Buprenorphine |b A Narrative Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.06.2023 | ||
| 500 | |a Date Revised 02.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE OF REVIEW: Opioid use disorder (OUD) is a chronic disorder in which a person loses control over the use of opioids, develops a compulsive behavior, and defends the use despite knowing the negative consequences. There are numerous treatments for OUD, including buprenorphine. Since it is displacing a full agonist opioid, precipitated withdrawal can occur with standard inductions involving buprenorphine | ||
| 520 | |a RECENT FINDINGS: Case reports have noted success with a low-dose initiation of buprenorphine, which is different from typical protocols, relatively limited by adverse effects when patients were recently administered full agonists. A cohort investigation studied the use of a transdermal patch as part of the protocol, which was fairly well tolerated. While ongoing research is being conducted on this topic, recent case studies and smaller cohort studies have demonstrated the feasibility of a trial to treat OUD with low-dose initiation of buprenorphine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Addiction treatment | |
| 650 | 4 | |a Buprenorphine | |
| 650 | 4 | |a Fentanyl | |
| 650 | 4 | |a Lose dose | |
| 650 | 4 | |a Opioid use disorder | |
| 650 | 4 | |a Withdrawal | |
| 650 | 7 | |a Buprenorphine |2 NLM | |
| 650 | 7 | |a 40D3SCR4GZ |2 NLM | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 700 | 1 | |a Fahmy, Omar H |e verfasserin |4 aut | |
| 700 | 1 | |a Spillers, Noah J |e verfasserin |4 aut | |
| 700 | 1 | |a Zaheri, Alexa R |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Eric D |e verfasserin |4 aut | |
| 700 | 1 | |a De Witt, Audrey J |e verfasserin |4 aut | |
| 700 | 1 | |a Wenger, Danielle M |e verfasserin |4 aut | |
| 700 | 1 | |a Cornett, Elyse M |e verfasserin |4 aut | |
| 700 | 1 | |a Skidmore, Kimberly L |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Adam M |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pain and headache reports |d 2001 |g 27(2023), 7 vom: 21. Juli, Seite 175-181 |w (DE-627)NLM111627923 |x 1534-3081 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:7 |g day:21 |g month:07 |g pages:175-181 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11916-023-01116-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 7 |b 21 |c 07 |h 175-181 | ||